IGXBIO
IGXBio, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.
IGXBIO
Industry:
Biotechnology Health Care Information Technology
Founded:
2001-01-01
Address:
Lenexa, Kansas, United States
Country:
United States
Website Url:
http://www.igxbio.com
Total Employee:
1+
Status:
Active
Contact:
(888)744-9246
Email Addresses:
[email protected]
Total Funding:
470 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt WordPress Nginx PHP PHP 7 WordPress 6.0
Investors List
Kansas Bioscience Authority
Kansas Bioscience Authority investment in Seed Round - IGXBio
More informations about "IGXBio"
IGXBio - Crunchbase Company Profile & Funding
IGXBio, Inc. is a biotechnology company developing advanced DNA immunotherapies for HIV infection.See details»
Home - IGM Biosciences
Nov 8, 2024 IGM Biosciences is pioneering a new class of antibody medicines for the treatment of autoimmune and inflammatory diseases. Building upon the greater binding power provided by the naturally occurring IgM antibody โฆSee details»
IGXBio Company Profile 2025: Valuation, Funding & Investors
IGXBio General Information Description. Developer of advanced DNA immunotherapies created to target HIV infection. The company's therapeutics is a proprietary DNA composition that โฆSee details»
IGM Biosciences - Crunchbase Company Profile & Funding
Organization. IGM Biosciences . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone โฆSee details»
IGM Biosciences - Overview, News & Similar companies - ZoomInfo
Who is IGM Biosciences. About IGM Biosciences: Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating an d โฆSee details»
About Us - IGM Biosciences
At IGM Biosciences, we believe that real innovation comes from looking beyond current approaches to envision a better way to address disease. Given the limitations of the widely โฆSee details»
IGM Biosciences - Devex
Learn more about IGM Biosciences's jobs, projects, latest news, contact information and geographical presence. IGM Biosciences is pioneering a new class of antibody medicines for โฆSee details»
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 โฆ
Mar 27, 2023 MOUNTAIN VIEW, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on โฆSee details»
Team Members Archive - IGM Biosciences
Dr. Harler joined IGM in 2021. She is our Chief Executive Officer and a member of our Board of Directors. Prior to joining IGM she was Senior Vice President, Head of Immunology and โฆSee details»
IGM Biosciences to Host Conference Call and Webcast to Provide โฆ
May 30, 2023 โ Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET โ. MOUNTAIN VIEW, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a โฆSee details»
IGM Biosciences Announces Strategic Pivot to Focus
Sep 30, 2024 โWe also want to sincerely thank Chris for his leadership of the clinical development organization as it expanded beyond oncology. We wish each of them the best in โฆSee details»
Strategic Pivot to Autoimmunity - IGM Biosciences
Imvotamab deeply depletes tissue-resident B cells in Non-Human Primates (NHPs) Non-human primate data presentations โข 2023 American College of Rheumatology (ACR) Convergence โฆSee details»
Elizabeth H.Z. Thompson, Ph.D. - IGM Biosciences
Dr. Thompson has served as a member of the board of California Life Sciences, a life sciences membership organization and was named to the PharmaVoice 100 list in 2023 and the โฆSee details»
IGM Biosciences Announces Fourth Quarter and Full Year 2021 โฆ
Mar 29, 2022 [email protected]. IGM Biosciences, Inc. Selected Statement of Operations Data (unaudited) (in thousands, except share and per share data) Three Months โฆSee details»
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on ...
Sep 30, 2024 --IGM Biosciences, Inc., a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline โฆSee details»
2024-09-30 | IGM Biosciences Announces Strategic Pivot to
Sep 30, 2024 IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology โฆSee details»
Kim Michelson - IGM Biosciences
Prior to joining IGM, she served as Senior Vice President of Clinical Operations at Medpace, a global drug, biologic and medical device clinical research organization. Ms. Michelson has also โฆSee details»
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare ...
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM โฆSee details»
Structure, Function, and Therapeutic Use of IgM Antibodies
Time were being given arbitrary names, in 1964 the World Health Organization de๏ฌned a nomenclature system for antibody isotypes. As a consequence -macroglobulin was renamed โฆSee details»
News Release - investor.igmbio.com
Apr 10, 2024 IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology and โฆSee details»